Good morning, everyone, and how are you today? We are doing just fine, thank you, now that a series of heavy downpours has cooled off the unusually steamy Pharmalot campus. A little rain can be a good thing, yes? Speaking of good things, the time has come to tackle two priorities: brewing more cups of stimulation (butter pecan is our choice, for the moment) and foraging for items of interest. On that note, here are a few tidbits. Hope your day is productive and satisfying, and do keep in touch. …
For the past year, 23andMe has been sharing its huge trove of genetic data with GlaxoSmithKline (GSK), which took a $300 million stake in the genetic testing company last summer, The Wall Street Journal notes. That collaboration has so far produced six potential drug targets and the companies expect to start human trials on at least one drug candidate next year. But it also raises ethical questions about using people’s genetic data to create profitable drugs.
About the Author Reprints
